Anavex og CNS
-
Anavex i Rettsymdromenews!
-
Anavex også i Multiple Sclerosis News Today!
Understreger, at 2-73 stadig i høj grad har pontentiale i MS.
Biogen omsætter for adskillige milliarder hvert år på området, men deres patenter løber ud om relative få år.Anavex er langt mere end en mulig behandling i en enkelt indikation!
Mulighederne for Anavex 2-73 er uanede, fordi det understøtter, beskytter og reetablere grundmekanismerne på et bredt område, som bl.a. nerveceller fungerer på.
Vi mangler bare den sidste vigtige bevis af, at de hidtil sete resultater kan eftervises i et større antal patienter.
MS Included in New US Patent Issued for Anavex 2-73
Anavex received a U.S. patent covering the use of Anavex 2-73 (blarcamesine) for the treatment of conditions including multiple sclerosis and Rett syndrome.
Multiple Sclerosis News Today (multiplesclerosisnewstoday.com)
Anavex 2-73 is an orally available, small-molecule activator of a protein called the sigma-1 receptor (S1R), which is essential to ensure correct protein folding within nerve cells and to promote neuroplasticity - the brain's ability to adapt or rewire following damage to preserve function.
The activation of S1R mediated by Anavex 2-73 is also thought to decrease mitochondria dysfunction, oxidative stress, and inflammation in the brain, potentially benefiting people with conditions like MS that damage the nervous system.
Mitochondria are the cell compartments responsible for the production of energy in the body. Oxidative stress refers to cellular damage that occurs as a result of having high levels of oxidant molecules. -
Anavex - oversigt patenter.
Illustrerer hvor omfattende et arbejde der ligger i, at beskytte sig mod at andre løber med ens forskning.
Bemærk at 4-5 af patenterne ligger i sidste halvdel af 2019.
Efter eget udsagn er Anavex dækket godt ind på dette område nu, men de seneste patenter kunne måske tyde på, at der evt. kan har været huller i beskyttelsen og at Anavex derfor har holdt lidt lav profil med resultater og udviklingen af de forskellige forsøg. - bare en formodning.
Det virker også positivt, at man bruger så meget energi på at beskytte 2-73 - man må da have en relativ stor tiltro til, at skidtet virker.Neurodevelopmental disorder therapy
Patent number: 10507196
Abstract: This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
Type: Grant
Filed: January 24, 2017
Date of Patent: December 17, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventor: Christopher U. MisslingCRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
Publication number: 20190350892
Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
Type: Application
Filed: July 29, 2019
Publication date: November 21, 2019
Applicant: ANAVEX LIFE SCIENCES CORP.
Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter YorkA19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
Patent number: 10441563
Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.
Type: Grant
Filed: October 19, 2015
Date of Patent: October 15, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventors: Missling U. Christopher, Durrant CameronCrystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
Patent number: 10426754
Abstract: Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73. Method of treatment of Alzheimer's disease using pharmaceutical compositions comprising ANAVEX2-73 according to an intermittent dosage regimen.
Type: Grant
Filed: June 14, 2017
Date of Patent: October 1, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventor: Marco CecchiCrystal forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
Patent number: 10413519
Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3 -furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2 -diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
Type: Grant
Filed: July 19, 2016
Date of Patent: September 17, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter YorkAnalgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
Patent number: 10195192
Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof ("AV1066"), with reference to visceral and neuropathic pain.
Type: Grant
Filed: November 1, 2016
Date of Patent: February 5, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventor: Christopher U. MisslingANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
Patent number: 9750746
Abstract: This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.
Type: Grant
Filed: July 12, 2013
Date of Patent: September 5, 2017
Assignee: Anavex Life Sciences Corp.
Inventors: Alexandre Vamvakides, Tangui MauriceNEW SIGMA-RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR BIOCHEMICAL MECHANISMS WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION
Publication number: 20170129864
Abstract: The present invention involves new and original sigma receptors ligands: (Mono-or di-alkylaminoalkyl)-?-butyrolactones, their analogues aminotetrahydrofuranes, the (1-adamantyl) phenyl(s) alkylamines, the N,N Dialkyl ?-[(adamantyl-l)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or alkyl phenylamines, their enantiomers or diastereoisomers and their pharmaceutically acceptable salts, with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with anti-cancer, anti-metastatic, anti-(chronic) inflammatory, neuro-protective, anticonvulsive, antidepressive and nooanaleptic or sedative action.
Type: Application
Filed: February 26, 2013
Publication date: May 11, 2017
Applicant: Anavex Life Sciences Corp.
Inventor: Alexandre VamvakidesSigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity
Patent number: 9180106
Abstract: The present invention involves new and original sigma receptors ligands: (Mono- or dialkylaminoalkyl)-?-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl)benzene alkylamines, the N,N Dialkyl ?-[(adamantyl-1)benzyloxy-2]alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or -alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.
Type: Grant
Filed: March 12, 2014
Date of Patent: November 10, 2015
Assignee: Anavex Life Sciences Corp.
Inventor: Alexandre VamvakidesANAVEX2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITORS COMPOSITION AND METHOD FOR NEUROPROTECTION
Publication number: 20140296211
Abstract: This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.
Type: Application
Filed: July 12, 2013
Publication date: October 2, 2014
Applicant: ANAVEX LIFE SCIENCES CORP.
Inventors: Alexandre Vamvakides, Tangui MauriceSIGMA RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTI-CANCER ACTIVITY
Publication number: 20140228375
Abstract: The present invention involves new and original sigma receptors ligands: (Mono-or dialkylaminoalkyl)-?-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl ?-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.
Type: Application
Filed: March 12, 2014
Publication date: August 14, 2014
Applicant: Anavex Life Sciences Corp.
Inventor: Alexandre Vamvakides -
PTI - møde med UK myndigheder.
Grønt lys for fase 3 forsøg i UK.
The MHRA's scientific advice outlined a clear path forward toward the initiation and execution of the proposed two-pronged Phase 3 program,
-
Tasso, bare af almindelig interesse https://www.fiercebiotech.com/biotech/biogen-makes-another-alzheimer-s-bet-paying-pfizer-75m-for-early-phase-drug
-
Biogen har måske erkendt, at de må spille på andre heste også på Alzheimer området, hvis de ikke kan få presset FDA til at godkende fejlede aducanumab på bagrund af de meget tvivlsomme resultater.
Man forventede ellers et årlig salg på 12 milliarder $ ved en godkendelse af aducanumab.
Fortæller noget om, hvor stort potentialet er for den, der løser gåden helt eller bare delvis.Ser måske ud til, at den seneste medie omtale af Anavex i Forbes og MoneyShow top Picks for 2020 - og annoncering af patent m.m. begynder at give en vis effekt.
Volumen og kursen går da i den rigtig retning pt.
Profitable Advice from Investing and Trading Experts
Daily articles and videos featuring specific investment recommendations, stock picks and ETF recommendations for investors plus profitable trading strategies and trade ideas from top investing and trading experts.
Profitable Advice from Investing and Trading Experts (www.moneyshow.com)
-
Bedre link Anavex - Forbes/MoneyShow
7 Hot Drug Stocks To Buy In 2020
Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their favorite stocks for the coming year. Here are seven favorites from the pharmaceutical and biotechnology space.
Forbes (www.forbes.com)
-
Antyder du at BIIB har tilkøbt til eller frasolgt kandidater fra deres pipeline (se link). Sådan læste jeg din kommentar.
Jeg har ikke kunnet finde oplysninger, der bekræfter dette. Har du evt. et link?
-
Thorkild01 - link.
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug
-
Tak tasso 1, og iøvrigt 1000 tak for den store indsats du yder mht. at holde os andre godt opdateret ang. AVLX. Før jeg begyndte at læse dine indlæg, havde jeg således ikke haft kig på selskabet, som jeg ligesom du finder yderst interessant.
-
Tasso1, nyt fra Novo. Kan ikke læse det hele: https://borsen.dk/nyheder/virksomheder/artikel/1/394261/investor_novo_nordisk_bekraefter_gennembrud_i_alzheimers.html?utm_source=forside&utm_campaign=nyhed_01
-
AVXL institutional Ownership fra 23,7 % til 35,66 %!
Dvs. en forøgelse på hele 50 % fra 3. til 4. kvartal!
Med den volumen der har været hidtil her i januar, kunne denne andel nu være endnu højere.
Det er så åbenbart ikke kun undertegnende, der har været så tosset og har købt yderliger op.Pr. 31/12 2019
MM - Kan heller ikke læse indholdet af Børsen, men spændende hvilken tilgang der anvendes.
-
Avxl. Man kan se at sorterne har svært ved at styre den sidste tid. De kan ikke blive ved at låne, det må stoppe på et tidspunkt. Jeg finder ud af det lørdag, min biblioteks dag, Novos tilgang
-
Avxl - Ja shorterne skal arbejde lidt hårdere nu, men tror ikke de sådan giver op.
En god pr. nu fra Anavex, ville nok sætte dem lidt yderligere under pres.
Kender ikke Gurufocus og mener egentlig først man kan se institutional andel den 15. februar - 1 1/2 måned efter sidste kvartal.
Måske man kan se andelen/størrelsen tidligere, men så bare uden udspecificering af navnene på fordelingen.
Men forudsat at siden er valid er antallet steget fra 13,30 mill. til 18,77 i sidste kvartal. - en stigning på kun 40,9 %, men med lidt flere aktier i omløb.Fint hvis du kunne komme med en tilbagemelding vedr. Novo MM.
Citat fra Børsen:
Selv om der er spæde tegn på, at Novo Nordisk har et lægemiddel, der virker på Alzheimers, så opfordrer medicinalanalytiker Jannick Lindegaard Denholt til, at man tager nyheden med et gran salt, da der fortsat er tale om meget tidlige indikationer om...
-
Avxl: mere om Novo https://m.medwatch.dk/article/11878405
-
Og her er de sidste nye ejere https://www.nasdaq.com/market-activity/stocks/avxl/institutional-holdings
-
Anavex - fra buy til strong buy.
Bare Zacks, men trods alt et godt signal at udsende.
https://www.zacks.com/stock/quote/AVXL?q=avxl
PTI kommer med resultater på deres precision CF forsøg på søndag den 19. januar.
Her et fint skriv over casen - skribenten har aktier i PTI, men synes han kommer med en del nyttig fakta:Fint med NOVO TDT - var en af mine første Biotek aktier og fornem at et dansk selskab er ledende på diabetis området.
Håber også det på sigt vil lykkes vedr. Alzheimer - men ren gevinst mæssig ville det give en noget større procent del, hvis det skulle lykkes for lille Anavex på samme område. Novo er jo relative store i forvejen og ville på sigt måske stige på den gode side af 100 % - Anavex måske flere 1000 %.
Mener også at Anavex er noget længere fremme - man vil nok kunne fange NOVO senere.Tror der er kommet nye ejer til efter den 30/9 2019 - iflg. Gurufocus er der købt ekstra 5,4 mill. aktier frem til 31/12 2019.
Her bliver navne først opgivet den 15. feb, medmindre den enkelt når op på mere end 5 % andel - så mener jeg de har 3-5 dage til at annoncerer dette. -
Tror godt jeg tør at lægge hovedet på blokken, og SKRIVE TAK FOR DENNE GANG 3$ håber aldrig jeg ser dig igen..
Volumen er 3 dobbelt de sidste mange børsdage. Om det er større spillere alene der driver volumen, eller forbes artiklen og større kendskab til lille anavex, vil jeg ikke gætte på. Jeg håber så meget på at de rammer jackpot, de har menneskeheden og min konto fortjent, selvfølglig også mine bio venner her på proinvestor.... Bemærk: selvfølgelig kan fejlende forsøg sende den under 3 igen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind